Health Care · Biological Products, (No Diagnostic Substances)

IMVT Immunovant, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1764013100 filings
Russell 2000

IMVT at a glance

Immunovant, Inc. (IMVT, SEC CIK 1764013) filed its latest 10-K annual report on May 20, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Immunovant, Inc. (IMVT) shares worth $1.2 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Pande Atul on November 11, 2026 of 3,000 shares at $36.00 per share.
  • In the last 90 days, IMVT insiders reported 0 open-market purchases ($0) and 10 open-market sales ($896K) on Form 4, a net sale of $896K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 10 sells
Net −$896K
13F holders
27 funds
$1.2B · −2 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, reflecting no commercialized products
  • Net loss $97.2M vs $126.5M YoY, operating expenses $104.2M vs $131.8M
  • Best R&D area, endocrine $22.5M; worst, neurological $18.3M, both down YoY
  • Cash $722.3M vs $902.1M at March 31; operating cash used $207.6M
  • Cash expected to fund operations through potential GD launch; expanded development could shorten runway

Risk Factors

  • No material risk-factor changes during quarter ended September 30, 2026
  • Carried-forward risks include potential adverse effects on business, operations, financial condition and cash flows
  • Share-price risk: adverse events could reduce Immunovant common-stock value
  • Investment risk: shareholders could lose all or part of their investment

AI summary of the IMVT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal Q2 and six months ended September 30, 2026 financial results announced
  • Press release dated November 9, 2026 contains the results and accompanying management disclosures

Item EX-99.1: Item EX-99.1

  • IMVT-1402 600 mg met primary ACR20 endpoint in D2T RA: 92.5% vs 75.6% placebo, p=0.0139
  • Dose differentiation emerged: 300 mg showed no placebo advantage, with 75.0% ACR20 response, p=0.9426
Filed Sep 3, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • 198,373,370 shares represented, approximately 96% of eligible voting shares, indicating strong shareholder participation
  • Bauer, Hughes, and Susman re-elected to the Board through the 2027 annual meeting
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • IMVT-1402 timelines remain on track across six autoimmune indications, with GD and MG topline data expected in 2027
  • Cash $797.8M supports potential IMVT-1402 launch in GD, but quarterly cash declined from $902.1M at March 31, 2026

Item 2.02: Results of Operations and Financial Condition

  • Fiscal first-quarter results for the period ended June 30, 2026
  • Press release provides Immunovant’s financial results and management commentary as Exhibit 99.1

AI summaries of IMVT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IMVT

Don't miss the next IMVT filing

  • Alerts as it files. A push when IMVT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IMVT, by share count.
  • Ask anything. An AI agent that reads every IMVT filing and answers with sources.

IMVT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Pande AtulSellNov 11, 2026$36.00
Pande AtulMNov 11, 2026-
Pande AtulMNov 11, 2026$8.43
Girao TiagoSellOct 28, 2026$28.50
Stout Jay SSellOct 21, 2026$28.94
Stout Jay SSellOct 7, 2026$32.06
Stout Jay SSellOct 7, 2026$32.06
Van Tuyl ChristopherSellOct 7, 2026$32.06

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Net Income-$259.3M-$413.8M-$505.6M
Balance Sheet
Total Assets$666.4M$776.2M$957.0M
Equity$617.8M$707.4M$852.6M
ROE-42.0%-58.5%-59.3%
Per Share
EPS$-1.88$-2.73$-2.77
Cash Flow
Operating CF-$214.2M-$375.9M-$407.3M
CapEx$360K$759K$8K

Source: XBRL data in Immunovant, Inc. (IMVT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate IMVT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
IMVT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$1.16B
Q2 202629$1.89B
Q1 202625$1.09B
Q4 202520$1.11B
Q3 202520$595.0M
Q2 202523$660.1M
Q1 202522$600.7M
Q4 202420$704.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 186 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

IMVT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
4Oct 30, 2026--
4Oct 23, 2026--
4Oct 9, 2026--
4Oct 9, 2026--
4Oct 9, 2026--
4Oct 5, 2026--
4Sep 25, 2026--
8-KSep 3, 2026Analysis-
4Aug 28, 2026--
4Aug 21, 2026--
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Jul 24, 2026--
4Jul 24, 2026--
4Jul 24, 2026--
4Jul 10, 2026--
4Jul 10, 2026--
4Jul 10, 2026--
4Jul 6, 2026--
4Jun 26, 2026--
4Jun 26, 2026--
4Jun 26, 2026--

Related Health Care companies

All Health Care →

IMVT SEC filings: frequently asked questions

Are IMVT insiders buying or selling?

In the last 90 days, Immunovant, Inc. (IMVT) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $895,852 by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold IMVT stock?

As of September 30, 2026, the largest Immunovant, Inc. (IMVT) holders among the 13F filers tracked by SignalX were BlackRock ($250.8 million), Morgan Stanley ($192.0 million), Vanguard Portfolio Management LLC ($144.1 million), State Street Corp ($141.8 million), Vanguard Capital Management LLC ($138.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did IMVT report in its latest 8-K?

Immunovant, Inc. (IMVT) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal Q2 and six months ended September 30, 2026 financial results announced.

What are the latest IMVT SEC filings?

Immunovant, Inc. (IMVT) filed its latest 10-K annual report on May 20, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 12, 2026.

What is IMVT's SEC CIK number?

Immunovant, Inc. (IMVT)'s SEC Central Index Key (CIK) is 1764013. EDGAR lists every IMVT filing under that number.

Ask anything about IMVT

The research agent reads IMVT's filings, financials, insider trades and 13F holders, then answers with sources.